IMS Health Holdings Inc

IMS Health — Q4 2014 Earnings Presentation

22 slides from IMS Health's earnings presentation, Feb 3, 2015

  1. Slide 1: IMS Health Q4 2014 Earnings Call

    IMS Health Q4 2014 Earnings Call February 3, 2015 IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.

  2. Slide 2: Legal

    Legal This presentation should be viewed in conjunction with IMS Health’s Q4 2014 earnings call Safe Harbor Statement This presentation includes “forward-looking statements”, including statements regarding future financial and operating results, especially those set forth under the heading “Full-Yea

  3. Slide 3: 4th Quarter Results

    4th Quarter Results $M Revenue EBITDA +6 2% +6.2% +8 5% +8.5% @ CFx @ CFx $678 $674 $214 $ $211 Q4 2014 Q4 2013 Q4 2014 Q4 2013 Note: Dollars are actual foreign exchange rates. CFx is constant currency. EBITDA is “Adjusted EBITDA” as defined in the IMS Health earnings release IMS Health Confidential

  4. Slide 4: Cegedim Update

    Cegedim Update Status Financials  Works council information and Revenue consultation lt ti requirements i t 42% Information  Cegedim Board of Directors approval 25% Other 33% Tech Svs  Fully executed Definitive Purchase Agreement 2013 Financials ((1)) Revenue: $491M  U.S. and Europe regulatory a

  5. Slide 5: 4th Quarter Offering Revenue

    4th Quarter Offering Revenue Offering 4th Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Information $366 $387 0.8% (5.5%) Technology Services $312 $287 13.6% 8.8% Total $678 $674 6.2% 0.6% IMS Health Confidential. Do not distribute outside your organization. 5 (c) 2015 IMS Health

  6. Slide 6: 4th Quarter Geographic Revenue

    4th Quarter Geographic Revenue Geography 4th Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Developed Markets $565 $560 5.5% 0.9% Emerging Markets $113 $114 9.7% (1.0%) Total $678 $674 6.2% 0.6% IMS Health Confidential. Do not distribute outside your organization. 6 (c) 2015 IMS H

  7. Slide 7: 4th Quarter EBITDA

    4th Quarter EBITDA 4th Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Adjusted EBITDA (1) $214 $211 8.5% 1.1% Adjusted EBITDA 31.6% 31.4% 68 bps 18 bps margin g (1) See reconciliations of non-GAAP items in appendix IMS Health Confidential. Do not distribute outside your organizati

  8. Slide 8: 4th Quarter P&L

    4th Quarter P&L At reported FX rates $M (except per share data) 2014 2013 Net Income / (Loss) $8 $82 Diluted Earnings / (Loss) per Share $0.03 $0.29 Adjusted Net Income (1) $125 $79 Adjusted Diluted Earnings per Share (1) $0.36 $0.28 (1) See reconciliations of non-GAAP items in appendix IMS Health C

  9. Slide 9: Full-Year Revenue

    Full-Year Revenue Offering Full-Year Versus Prior Year Constant $M 2014 2013 Reported Currency Information $1,515 $1,525 1.7% (0.7%) Technology Services $1,126 $1,019 12.3% 10.6% Total $2,641 $2,544 5.9% 3.8% Geography Full-Year Versus Prior Year Developed Markets $2,181 $2,107 4.9% 3.5% Emerging Ma

  10. Slide 10: Full-Year P&L

    Full-Year P&L At reported FX rates $M (except per share data) 2014 2013 Adjusted EBITDA (1) $878 $829 Adj t d EBITDA margin Adjusted i 33 2% 33.2% 32 6% 32.6% Net Income / (Loss) $(189) $82 Diluted Earnings / (Loss) per Share $(0.59) $0.29 Adjusted Net Income (1) $454 $385 Adjusted Diluted Earnings

  11. Slide 11: 4th Quarter Balance Sheet Items & Metrics

    4th Quarter Balance Sheet Items & Metrics $M 2014 2013 Cash & Cash Equivalents & Short-Term $390 $729 (1) I Investments t t (3) Principal Balance of Debt (2) $3,816 $5,027 (1) Net Debt $3,426 $4,298 (1) Gross Leverage Ratio 4.3x 6.1x (1) Cash Provided by Operating Activities $147 $78 Capital Expendi

  12. Slide 12: 2014 Foreign Currency Impact

    2014 Foreign Currency Impact Core IMS Reported vs. constant currency (reported < constant currency), currency) reported > constant currency Growth rate FY 2014 Constant impact of FX Q1 Q2 Q3 Q4 FY Currency Growth Revenue (1.4)% 0.7% (1.7)% (5.6)% (2.1)% 5.9% Adjusted (2.3)% (0.1)% (4.4)% (7.4)% (3.6

  13. Slide 13: 1st Quarter 2015 Foreign Currency Impact

    1st Quarter 2015 Foreign Currency Impact Core IMS Reported vs. constant currency (1) (reported < constant currency), currency) reported > constant currency Growth rate impact of FX Q1 Revenue (8.4)% Adjusted (9.6)% EBITDA (1) Assuming current exchange rates remain unchanged to the end of the first q

  14. Slide 14: Full-Year 2015 Guidance

    Full-Year 2015 Guidance Core IMS IMS w/Acquisition (2) Constant Currency Constant Currency Reported (1) Revenue Growth 5 - 6% 19 - 20% 11 - 12% Adjusted EBITDA 7.5 - 8.5% 13 - 14% 5 - 6% Growth Adjusted Net Income Growth 16 - 19% 20 - 23% 8 - 11% Adjusted Diluted 11 - 14% 15 - 18% 4 - 6% EPS (1) A A

  15. Slide 15: Q&A

    Q&A IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.

  16. Slide 16: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.

  17. Slide 17: Net Income to Adjusted EBITDA

    Net Income to Adjusted EBITDA Three Months Ended Twelve Months Ended December 31, December 31, (in millions) 2014 2013 2014 2013 Net Income (Loss) $ 8 $ 82 $ (189) $ 82 Provision for (benefit from) income taxes 45 (124) (96) (130) Other (income) loss, net(1) (5) 30 276 74 Interest expense 40 91 221

  18. Slide 18: Net Income to Adjusted Net Income & Per Share Data

    Net Income to Adjusted Net Income & Per Share Data Three Months Ended Twelve Months Ended December 31, December 31, (in millions, except per share data) 2014 2013 2014 2013 Net Income (Loss) $ 8 $ 82 $ (189) $ 82 Provision for (benefit from) income taxes 45 (124) (96) (130) Amortization associated w

  19. Slide 19: Unlevered Free Cash Flow

    Unlevered Free Cash Flow Three Months Ended Twelve Months Ended December 31, December 31, (in millions) 2014 2013 2014 2013 Net Cash (Used in) Provided by Operating $ 147 $ 78 $ 110 $ 414 A ti iti Activities Capital expenditures (13) (16) (72) (41) Additions to computer software (25) (28) (95) (81)

  20. Slide 20: Gross Leverage Ratio

    Gross Leverage Ratio December 31, 2014 (in millions) Gross Debt $ 3,816 Adj t d EBITDA (f Adjusted (for th the ttwelve l months th ended d d December D b 31, 31 2014) $ 878 Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA) 4.3x IMS Health Confidential. Do not distribute outside your organization

  21. Slide 21: Non-GAAP Adjustments By Income Statement Line Items

    Non-GAAP Adjustments By Income Statement Line Items Three Months Twelve Months Ended Ended December 31, December 31, (in millions) 2014 2013 2014 2013 Non-GAAP adjustments included in: Operating costs of information, exclusive of 2 2 21 9 depreciation and amortization Direct and incremental costs of

  22. Slide 22: END

    END IMS Health Confidential. Do not distribute outside your organization. 22 (c) 2015 IMS Health Incorporated. All Rights Reserved.

IMS Health — Q4 2014 Earnings Presentation on 6ix